Biomarkers that can play an important role in identifying the initial stages of DCM comprise serum inflammatory agents like interleukins, TNF-α, and C-reactive protein (CRP); increased fibrosis-related biomarkers such as transforming growth factor-beta (TGF-β) and insulin-like growth factor binding protein 7 (IGFBP-7); and diminished antioxidant agents such as adiponectin and leptin [42]. This evidence concerns the gene TGFB1 and familial dilated cardiomyopathy.